(2020). Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports. Reactions Weekly.
Citación estilo Chicago"Ipilimumab/nivolumab: Immune-related Pneumonitis: 2 Case Reports." Reactions Weekly 2020.
Cita MLA"Ipilimumab/nivolumab: Immune-related Pneumonitis: 2 Case Reports." Reactions Weekly 2020.
Precaución: Estas citas no son 100% exactas.